ArticlePlastic and reconstructive surgery. Global open2024
The Use of NovoSorb BTM for Trauma Reconstruction: Illustrative Cases and a Proposed Decision-making Tool.
Article in Plastic and reconstructive surgery. Global open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Biodegradable Temporizing Matrix Use Over an Exposed Lower Limb Joint.Plastic and reconstructive surgery. Global open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving a functional and aesthetic reconstruction following complex trauma is a challenge. Skin substitutes, including acellular dermal matrices, and newer, synthetic options such as NovoSorb biodegradable temporizing membrane (BTM) have given the reconstructive surgeon a useful tool where autologous options have been exhausted, are inappropriate, or would present a suboptimal reconstruction. This case series describes 6 patients admitted to an urban level I major trauma center between July and December 2022. All patients underwent complex reconstructive lower limb surgery using BTM as either a primary or salvage option. In each case, this approach was chosen on a case-by-case basis where it was felt BTM would offer a reconstructive advantage, or where primary reconstructive options had been exhausted. Data were collected retrospectively from case notes. Three patients received BTM as a primary reconstructive option. BTM integrated successfully in all 3. Three patients received BTM as a salvage option. In 1, the exposed fracture site was successfully bridged, and in another, BTM was successfully reapplied over exposed fracture site where BTM had previously failed to incorporate. Although BTM is a relatively new tool in the reconstructive surgeon's armamentarium, requiring further research into long-term outcomes, cost-effectiveness, and patient satisfaction, it can be a useful and versatile tool.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.